Education
About Us
Working with TipRanks
Follow Us
Tempus AI, Inc. Class A (TEM)
NASDAQ:TEM
TEM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$31.36 - $91.45
Previous CloseN/A
Volume1.41M
Average Volume (3M)9.87M
Market Cap
$10.57B
Enterprise Value$10.10B
Total Cash (Recent Filing)$218.79M
Total Debt (Recent Filing)$857.75M
Price to Earnings (P/E)―
Beta3.06
Next Earnings
Aug 08, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding168,072,450
10 Day Avg. Volume8,899,851
30 Day Avg. Volume9,874,237
Financial Highlights & Ratios
PEG Ratio-4.28
Price to Book (P/B)29.41
Price to Sales (P/S)0.00
P/FCF Ratio-44.47
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue3.70
Enterprise Value/Gross Profit22.32
Enterprise Value/Ebitda-3.99
Forecast
1Y Price Target
$68.86Price Target Upside12.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Tempus AI, Inc. Class A News
Bulls Say, Bears Say
Bulls Say
Revenue GrowthOverall core 'Genomics' revenue grew 27% year-over-year, led by higher average selling prices.
Strategic AgreementsShares of TEM are up +16% on news that the company signed a $200 million expanded strategic agreement with AstraZeneca and Pathos AI.
Bears Say
Cash FlowQuarterly cash flow from operations was roughly -$106 million, largely due to timing of cash flows and 'one-timers' with Ambry.
Revenue EstimatesTotal revenue fell short of estimates by roughly 2% on the data and services side.
Ownership Overview
42.73% Insiders
6.17% Mutual Funds
0.11% Other Institutional Investors
39.96% Public Companies and Individual Investors
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $31.36 and its highest was $91.45 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Tempus AI, Inc. Class A’s market cap is $10.57B.
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
Tempus AI, Inc. Class A’s upcoming earnings report date is Aug 08, 2025 which is in 15 days.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Tempus AI, Inc. Class A released its earnings results on May 06, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.26 by $0.02.
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Undervalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate is -0.23.
How many shares outstanding does Tempus AI, Inc. Class A have?
Tempus AI, Inc. Class A has 168,072,450 shares outstanding.
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Tempus AI, Inc. Class A reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.26. Following the earnings report the stock price went up 12.589%.
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Currently, no hedge funds are holding shares in TEM
Tempus AI, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$68.86 (12.74% Upside)
$68.86 (12.74% Upside)
Blogger Sentiment
Bullish
TEM Sentiment 81%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 2.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.4%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.11%
12-Months-Change
Fundamentals
Return on Equity
-1252.79%
Trailing 12-Months
Asset Growth
228.84%
Trailing 12-Months
Company Description
Tempus AI, Inc. Class A
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
TEM Company Deck
TEM Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant year-over-year growth in revenue, gross profit, and genomic segments, alongside improved adjusted EBITDA and strong guidance for future growth. The partnership with AstraZeneca and Pathos is seen as a major achievement. However, challenges remain with a negative adjusted EBITDA and the need to meter MRD volumes due to reimbursement issues.Read More>TEM Stock 12 Month Forecast
Average Price Target
$68.86
▲(12.74%Upside)